Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
21
BXC Quote, Financials, Valuation and Earnings
Last price:
$65.10
Seasonality move
:
-0.43%
Day range:
$63.55 - $69.58
52-week range:
$63.55 - $134.79
Dividend yield:
0%
P/E ratio:
10.61x
P/S ratio:
0.19x
P/B ratio:
0.84x
Volume:
280K
Avg. volume:
108K
1-year change:
-40.6%
Market cap:
$540.3M
Revenue:
$3B
EPS (TTM):
$6.14
Analysts' Opinion
-
Consensus RatingBlueLinx Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $121.75, BlueLinx Holdings has an estimated upside of 86.91% from its current price of $65.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 100% downside risk from its current price of $65.14.
Fair Value
-
According to the consensus of 4 analysts, BlueLinx Holdings has 86.91% upside to fair value with a price target of $121.75 per share.
BXC vs. S&P 500
-
Over the past 5 trading days, BlueLinx Holdings has underperformed the S&P 500 by -9.69% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BlueLinx Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BlueLinx Holdings revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter BlueLinx Holdings reported revenues of $710.6M.
Earnings Growth
-
BlueLinx Holdings earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter BlueLinx Holdings reported earnings per share of $0.62.
Enterprise value:
329.8M
EV / Invested capital:
--
Price / LTM sales:
0.19x
EV / EBIT:
4.04x
EV / Revenue:
0.11x
PEG ratio (5yr expected):
0.73x
EV / Free cash flow:
7.32x
Price / Operating cash flow:
12.39x
Enterprise value / EBITDA:
2.75x
Gross Profit (TTM):
$489.1M
Return On Assets:
3.36%
Net Income Margin (TTM):
1.8%
Return On Equity:
8.19%
Return On Invested Capital:
5.63%
Operating Margin:
1.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $4.5B | $3.1B | $3B | $712.5M | $710.6M | |
| Gross Profit | $833M | $527M | $489.1M | $118.4M | $113.3M | |
| Operating Income | $438.9M | $138.4M | $87.3M | $27.2M | $11.8M | |
| EBITDA | $464.6M | $134.1M | $120.1M | -$10M | -$224K | |
| Diluted EPS | $30.55 | $5.36 | $6.14 | -$1.99 | $0.62 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $668.4M | $945.2M | $1.1B | $1.1B | $1.1B | |
| Total Assets | $1B | $1.3B | $1.5B | $1.5B | $1.6B | |
| Current Liabilities | $229M | $243.8M | $210.7M | $218.6M | $233.7M | |
| Total Liabilities | $989M | $954.2M | $900M | $903.3M | $931.3M | |
| Total Equity | $59.1M | $363.2M | $590M | $634.3M | $646.4M | |
| Total Debt | $322.4M | $291.3M | $292.4M | $293.7M | $295.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $400.3M | $306.3M | $85.2M | $75.6M | $18.7M | |
| Cash From Investing | -$98.7M | -$26.9M | -$39.2M | -$8.1M | -$20.2M | |
| Cash From Financing | -$87.9M | -$56.6M | -$62.1M | -$15.5M | -$19.2M | |
| Free Cash Flow | $364.4M | $278.8M | $45.1M | $67M | -$1.5M | |
BXC
Sector
Market Cap
$540.3M
$588.9M
Price % of 52-Week High
48.33%
72.6%
Dividend Yield
0%
0%
Shareholder Yield
5.7%
2.44%
1-Year Price Total Return
-40.6%
-8.43%
Beta (5-Year)
1.995
0.764
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$71.35
200-day SMA
Sell
Level
$100.73
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$71.76
Relative Strength Index (RSI14)
Sell
Level
32.26
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-87.28
50-day SMA
Sell
Level
$77.75
MACD (12, 26)
Sell
Level
-2.46
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7539)
Buy
CA Score
(Annual)
Level (0.1326)
Buy
Beneish M-Score
(Annual)
Level (-2.6257)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.1163)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
Stock Forecast FAQ
In the current month, BXC has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BXC average analyst price target in the past 3 months is $121.75.
-
Where Will BlueLinx Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that BlueLinx Holdings share price will rise to $121.75 per share over the next 12 months.
-
What Do Analysts Say About BlueLinx Holdings?
Analysts are divided on their view about BlueLinx Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BlueLinx Holdings is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is BlueLinx Holdings's Price Target?
The price target for BlueLinx Holdings over the next 1-year time period is forecast to be $121.75 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BXC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BlueLinx Holdings is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BXC?
You can purchase shares of BlueLinx Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BlueLinx Holdings shares.
-
What Is The BlueLinx Holdings Share Price Today?
BlueLinx Holdings was last trading at $65.10 per share. This represents the most recent stock quote for BlueLinx Holdings. Yesterday, BlueLinx Holdings closed at $65.14 per share.
-
How To Buy BlueLinx Holdings Stock Online?
In order to purchase BlueLinx Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for May 1
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
53
EAT alert for May 1
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
